Sai Lifesciences Gets Target Price Hike From Morgan Stanley As Growth Outpaces Industry
Morgan Stanley hiked the target price of Sai Lifesciences, noting its higher-than-industry growth. The brokerage maintained an 'overweight' rating and hiked the target price to Rs 911 apiece from Rs 865. The current target price implies a 20.18% upside from Wednesday's closing price.
The CRDMO model of Sai Lifesciences is expected to enable the company to outpace the industry. The company said it had increased its capital expenditure sharply, implying confidence in future growth, according to the brokerage.
CRDMO stands for contract research, development, and manufacturing organisation.
Sai Lifesciences was able to grow its contract research business 26% year-on-year in financial year 2025 even as funding in the biotechnology environment softened. The discovery segment contributed 37% to the topline. In the contract manufacturing segment, Sai Lifesciences has more than 90 projects in the pipeline, Morgan Stanley said.
With opportunities for high revenue, Sai Lifesciences is hiking investments in new capacities and modalities. Capital expenditure has been hiked from Rs 500 crore to Rs 700 crore in financial year 2026, Morgan Stanley said.
Sai Lifesciences Q4 Earnings Key Highlights (Consolidated, YoY)Â
Net profit rose 57.21% to Rs 88 crore vs Rs 56 crore.
Revenue rose 32% to Rs 579.5 crore vs Rs 439 crore.
Ebitda rose 26.5% to Rs 157.6 crore vs Rs 124.6 crore.
Margin at 27.2% vs 28.3%.
Morgan Stanley estimates the earnings-to-price ratio to dip to 6.0% and 84%, respectively, for financial years 2026 and 2027. The brokerage built in lower other income and higher interest costs to account for increased capital expenditure.
Morgan Stanley valued Sai Lifesciences based on a one-year forward valuation of the CDMO sector, which is 59 times. The previous target price was aligned with Syngene International's one-year forward price-to-earnings ratio. The company's business is a mix of both contract research organisation and CDMO, whereas Syngene International is more CRO-focused.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.